Company Description
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs.
The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA.
It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients.
The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016.
Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
| Country | United States |
| Founded | 2011 |
| IPO Date | Sep 29, 2016 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,184 |
| CEO | Ming Hsieh |
Contact Details
Address: 4399 Santa Anita Avenue El Monte, California 91731 United States | |
| Phone | 626 350 0537 |
| Website | fulgentgenetics.com |
Stock Details
| Ticker Symbol | FLGT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001674930 |
| CUSIP Number | 359664109 |
| ISIN Number | US3596641098 |
| Employer ID | 81-2621304 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Ming Hsieh | Chairman and Chief Executive Officer |
| Jian Xie | Chief Operating Officer and President |
| Dr. Hanlin Gao D.A.B.M.G., FACMG, M.D., Ph.D. | Chief Scientific Officer and Laboratory Director |
| Natalie Prescott | General Counsel and Chief Privacy Officer |
| Doreen Ng | Vice President of Operations and Compliance and GM of Houston Office |
| Jakub Sram | Vice President of Business Development and Sales |
| Ellen Tsui | Vice President of Human Resources |
| Brandon Perthuis | Chief Commercial Officer |
| Dr. Lawrence M. Weiss M.D. | Chief Medical Officer |
| Dr. Ray Yin | President and Chief Scientific Officer of Fulgent Pharma |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 8, 2024 | 10-Q | Quarterly Report |
| Nov 8, 2024 | 8-K | Current Report |
| Nov 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 3, 2024 | 144 | Filing |
| Sep 3, 2024 | 144 | Filing |
| Aug 27, 2024 | 144 | Filing |
| Aug 2, 2024 | 10-Q | Quarterly Report |
| Aug 2, 2024 | 8-K | Current Report |
| May 16, 2024 | 8-K | Current Report |
| May 3, 2024 | 10-Q | Quarterly Report |